Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.

Popovic V, Simic M, Ilic L, Micic D, Damjanovic S, Djurovic M, Obradovic S, Dieguez C, Casanueva F

Clinical endocrinology1 Jan 1998Cited by 4 (Europe PMC)

PMID9509075DOI10.1046/j.1365-2265.1998.00360.xPepBankPUB-09509075

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In patients with macroprolactinoma before treatment, the peak GH response to GHRP‑6 was significantly lower than in healthy subjects and patients with microprolactinoma.
In plain wordsIn people with large prolactin-producing pituitary tumours, GHRP‑6 raised growth hormone less than in healthy people and people with small tumours.
Peptide
GHRP-6
Outcome
DecreasePeak GH after GHRP-6 in macroprolactinoma before treatment
Study
n = 11
Comparator
Healthy subjects and patients with microprolactinoma
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
These values were all significantly different (P < 0.05) from normal subjects and patients with microprolactinomas with peak GH 16.8 +/- 0.9 mU/l after GHRH; 43 +/- 6 mU/l after GHRP-6 and 130 +/- 10 mU/l after GHRH + GHRP-6.
2 context sentences(design, population, supporting numbers)
Summary · context
Peak GH response before treatment in macroprolactinoma patients was 4.9 +/- 0.9 mu/l after GHRH, 8 +/- 4 mU/l after GHRP-6
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
Report a problemFND-0950907501
02HumanObservational studyEfficacy outcome
In patients with macroprolactinoma before treatment, the GH area under the curve after GHRP‑6 was significantly lower than in healthy subjects and patients with microprolactinoma.
In plain wordsIn people with large prolactin-producing pituitary tumours, total growth hormone release after GHRP‑6 was lower than in healthy people and people with small tumours.
Peptide
GHRP-6
Outcome
DecreaseGH area under the curve after GHRP-6 in macroprolactinoma before treatment
Study
n = 11
Comparator
Healthy subjects and patients with microprolactinoma
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
These values were all significantly different (P < 0.05) from normal subjects and patients with microprolactinomas with peak GH 16.8 +/- 0.9 mU/l after GHRH; 43 +/- 6 mU/l after GHRP-6 and 130 +/- 10 mU/l after GHRH + GHRP-6.
2 context sentences(design, population, supporting numbers)
Summary · context
AUC were 390 +/- 90; 500 +/- 100 and 1100 +/- 300 mU/l x 120 min respectively.
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
Report a problemFND-0950907502
03HumanObservational studyEfficacy outcome
Prolactin release stimulated by GHRP‑6 in healthy subjects was not seen in patients with micro- or macroprolactinomas.
In plain wordsGHRP‑6 raised prolactin in healthy people, but this rise was not seen in people with prolactin-producing pituitary tumours.
Peptide
GHRP-6
Outcome
No significant changeProlactin release after intravenous GHRP-6 in patients versus healthy subjects
Study
n: not reported in source
Comparator
Healthy subjects
Outcome group
Pituitary hormones · Endocrine and hormones
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Prolactin release stimulated by intravenous administration of GHRP-6 in healthy subjects was not seen in patients with micro- or macroprolactinomas.
1 context sentence(design, population, supporting numbers)
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
Report a problemFND-0950907510

Studies that did not test the peptide alone7

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

04HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with macroprolactinoma before treatment, the peak GH response to GHRH plus GHRP‑6 was significantly lower than in healthy subjects and patients with microprolactinoma.
In plain wordsIn people with large prolactin-producing pituitary tumours, GHRP‑6 plus GHRH raised growth hormone less than in healthy people.
Peptide
GHRP-6
Outcome
DecreasePeak GH after GHRH plus GHRP-6 in macroprolactinoma before treatment
Study
n = 11
Comparator
Healthy subjects and patients with microprolactinoma
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
These values were all significantly different (P < 0.05) from normal subjects and patients with microprolactinomas with peak GH 16.8 +/- 0.9 mU/l after GHRH; 43 +/- 6 mU/l after GHRP-6 and 130 +/- 10 mU/l after GHRH + GHRP-6.
2 context sentences(design, population, supporting numbers)
Summary · context
and 18 +/- 5 mU/l after GHRH + GHRP-6.
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907503
05HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with macroprolactinoma before treatment, the GH area under the curve after GHRH plus GHRP‑6 was significantly lower than in healthy subjects and patients with microprolactinoma.
In plain wordsIn people with large prolactin-producing pituitary tumours, total growth hormone release after GHRP‑6 plus GHRH was lower than in healthy people.
Peptide
GHRP-6
Outcome
DecreaseGH area under the curve after GHRH plus GHRP-6 in macroprolactinoma before treatment
Study
n = 11
Comparator
Healthy subjects and patients with microprolactinoma
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
These values were all significantly different (P < 0.05) from normal subjects and patients with microprolactinomas with peak GH 16.8 +/- 0.9 mU/l after GHRH; 43 +/- 6 mU/l after GHRP-6 and 130 +/- 10 mU/l after GHRH + GHRP-6.
2 context sentences(design, population, supporting numbers)
Summary · context
AUC were 390 +/- 90; 500 +/- 100 and 1100 +/- 300 mU/l x 120 min respectively.
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907504
06HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with macroprolactinoma before treatment, no synergism was seen between GHRH and GHRP‑6.
In plain wordsIn people with large prolactin-producing pituitary tumours, GHRP‑6 and GHRH did not boost each other's growth hormone effect.
Peptide
GHRP-6
Outcome
No significant changeSynergism of GHRH plus GHRP-6 in macroprolactinoma
Study
n = 11
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Synergism was absent.
1 context sentence(design, population, supporting numbers)
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907505
07HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with macroprolactinoma, the GH response to GHRP‑6 and to GHRH plus GHRP‑6 improved significantly after bromocriptine treatment.
In plain wordsIn people with large prolactin-producing pituitary tumours, the growth hormone response to GHRP‑6 improved after bromocriptine treatment.
Peptide
GHRP-6
Outcome
IncreaseGH response to GHRP-6 and to GHRH plus GHRP-6 in macroprolactinoma after bromocriptine
Study
n = 11
Comparator
Before bromocriptine
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The response of GH after GHRP-6 and GHRH + GHRP-6 improved significantly (P < 0.05) in treated patients with macroprolactinoma.
1 context sentence(design, population, supporting numbers)
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907507
08HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with microprolactinoma, the synergism between GHRH and GHRP‑6 was preserved, as in normal subjects.
In plain wordsIn people with small prolactin-producing pituitary tumours, GHRP‑6 and GHRH still boosted each other's growth hormone effect, as in healthy people.
Peptide
GHRP-6
Outcome
No significant changeSynergism of GHRH plus GHRP-6 in microprolactinoma
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
As in normal subjects, synergism was preserved in patients with microprolactinoma (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907506
09HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with microprolactinoma, the GH response to the tests did not change significantly after bromocriptine treatment.
In plain wordsIn people with small prolactin-producing pituitary tumours, the growth hormone response did not change significantly after bromocriptine treatment.
Peptide
GHRP-6
Outcome
No significant changeGH response in microprolactinoma after bromocriptine
Study
n = 9
Comparator
Before bromocriptine
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was no significant change in GH response in microprolactinoma patients after treatment with bromocriptine.
1 context sentence(design, population, supporting numbers)
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907508
10HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome
In patients with macroprolactinoma or microprolactinoma, the prolactin rise after GHRP‑6 did not change after bromocriptine treatment.
In plain wordsIn people with prolactin-producing pituitary tumours, the prolactin rise after GHRP‑6 was the same before and after bromocriptine treatment.
Peptide
GHRP-6
Outcome
No significant changeDelta prolactin after GHRP-6 before and after bromocriptine
Study
n: not reported in source
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
Delta prolactin after GHRP-6 did not change before and after bromocriptine treatment in patients with macroprolactinoma or microprolactinoma.
1 context sentence(design, population, supporting numbers)
Summary · context
Eleven patients with macroprolactinomas aged 41.2 +/- 4.8 years (range 24-75), nine patients with microprolactinomas aged 31.5 +/- 3.4 (range 22-53) and 13 healthy subjects aged 42.1 +/- 4.7 years (range 22-64) were studied.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0950907509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.